Remicade, Inflectra, Renflexis, Avsola

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name: ______________________________ **Date**: __________________________________
Patient's ID: _________________________________ **Patient's Date of Birth:** ________________
Physician's Name: ____
Specialty: ___________________________________ **NPI#:** ___________________________________
Physician Office Telephone: ___________________ **Physician Office Fax:** ____________________

<u>Referring</u> Provider Info: ❑ **Same as Requesting Provider**
Name: ____ **NPI#:** _______________________________
Fax: _________________________ **Phone:** ______________________

<u>Rendering</u> Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: ____ **NPI#:** _______________________________
Fax: _________________________ **Phone:** ______________________

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

<u>Required Demographic Information:</u>

Patient Weight: __________________________*kg*

*Patient Height:*___________________________*cm*

<u>Drug Information:</u>

*Strength/Measure*______________________________ *Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un
*Directions(sig)*_________________________________ *Route of administration*________________________
*Dosing frequency*______________________________

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Remicade, Inflectra, Renflexis SGM – 10/2021.

Site of Service Questions:

A. Indicate the site of service requested:
   - ❑ On Campus Outpatient Hospital
   - ❑ Off Campus Outpatient Hospital
   - ❑ Home based setting, *skip to Criteria Questions*
   - ❑ Community office, *skip to Criteria Questions*
   - ❑ Ambulatory infusion site, *skip to Criteria Questions*

B. Is the patient less than 18 years of age?
   ❑ Yes, *skip to Clinical Criteria Questions*
   ❑ No

C. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.*** ❑ Yes, *skip to Clinical Criteria Questions* ❑ No

D. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?
   ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.
   ❑ Yes, *skip to Clinical Criteria Questions* ❑ No

E. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
   ❑ Yes, *skip to Clinical Criteria Questions* ❑ No

F. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
   ❑ Yes, *skip to Clinical Criteria Questions* ❑ No

G. Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
   ❑ Yes, *skip to Clinical Criteria Questions* ❑ No

H. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?
   ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation. ❑ Yes ❑ No

Clinical Criteria Questions:

1. What is the prescribed drug? ❑ Remicade ❑ Avsola ❑ Inflectra ❑ Renflexis

2. What is the prescribed dose and frequency?

   a) **Loading dose:**

   ❑ Remicade 100 mg Quantity and Frequency: _______________
   ❑ Avsola 100 mg Quantity and Frequency: _______________
   ❑ Inflectra 100 mg Quantity and Frequency: _______________
   ❑ Renflexis 100 mg Quantity and Frequency: _______________
   ❑ Other _______________________________________

   b) **Maintenance dose:**

   ❑ Remicade 100 mg Quantity and Frequency: _______________
   ❑ Avsola 100 mg Quantity and Frequency: _______________
   ❑ Inflectra 100 mg Quantity and Frequency: _______________
   ❑ Renflexis 100 mg Quantity and Frequency: _______________
   ❑ Other _______________________________________

   c) **Dosing (other):** *Indicate all that apply.*

   ❑ This is a request for a change in dosing regimen.
   ❑ The requested quantity is supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines.
   ❑ The patient requires a dose above 5 mg per kg due to loss of response at current dose.
   ❑ The patient requires a dose above 3 mg per kg due to an incomplete response at current dose.

3. Has the patient been diagnosed with any of the following? *List continues on next page.*

   ❑ Moderately to severely active Crohn's disease (CD)
   ❑ Moderately to severely active ulcerative colitis (UC)
   ❑ Moderately to severely active rheumatoid arthritis (RA)
   ❑ Active ankylosing spondylitis (AS)
   ❑ Active axial spondyloarthritis
   ❑ Active psoriatic arthritis WITHOUT co-existent plaque psoriasis (PsA)
   ❑ Active psoriatic arthritis with co-existent plaque psoriasis (PsA)
   ❑ Moderate to severe plaque psoriasis
   ❑ Juvenile idiopathic arthritis
   ❑ Behcet's disease
   ❑ Granulomatosis with polyangiitis (Wegener's granulomatosis)
   ❑ Severe, refractory hidradenitis suppurativa
   ❑ Pyoderma gangrenosum
   ❑ Sarcoidosis
   ❑ Refractory Takayasu's arteritis
   ❑ Uveitis
   ❑ Reactive arthritis
   ❑ Immune checkpoint inhibitor (e.g., CTLA-4, PD-L1 inhibitor) toxicity
   ❑ Acute graft versus host disease
   ❑ Other _______________________________________

4. What is the ICD-10 code? _________

5. What is the patient's weight? _______kg or lbs ***(circle one)***

6. Is the patient currently receiving Remicade or a biosimilar? ❑ Yes ❑ No

Section A: All Requests

7. Will the requested drug be used in combination with any other biologic (e.g., Humira) or targeted synthetic disease-modifying anti-rheumatic drug (DMARD) (e.g., Olumiant, Otezla, Xeljanz)? ❑ Yes ❑ No

8. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic DMARD (e.g., Olumiant, Xeljanz) associated with an increased risk of tuberculosis (TB)? *If Yes, skip to #10* ❑ Yes ❑ No

9. Has the patient had a tuberculosis (TB) test (e.g., tuberculosis skin test [PPD], interferon-release assay [IGRA], chest x-ray) within 6 months of initiating therapy? *If Yes, skip to #12* ❑ Yes ❑ No

10. Does the patient have risk factors for tuberculosis (TB) (e.g., persons with close contact to people with infectious TB disease; persons who have recently immigrated from areas of the world with high rates of TB [e.g., Africa, Asia, Eastern Europe, Latin America, Russia]; children less than 5 years of age who have a positive TB test; groups with high rates of TB transmission [e.g., homeless persons, injection drug users, persons with HIV infection], or persons who work or reside with people who are at an increased risk for active TB [e.g., hospitals, long-term care facilities, correctional facilities, homeless shelters])? ❑ Yes ❑ No *If No, skip to #15*

11. Has the patient been tested for tuberculosis (TB) within the previous 12 months? ❑ Yes ❑ No

12. What were the results of the tuberculosis (TB) test?
❑ Positive for TB ❑ Negative for TB, *skip to #15* ❑ Unknown

13. Does the patient have latent or active tuberculosis (TB)? ❑ Latent ❑ Active ❑ Unknown

14. Has treatment for latent tuberculosis (TB) infection been initiated or completed?
❑ Yes - treatment initiated ❑ Yes - treatment completed ❑ No

15. Is this request for continuation of therapy with the requested drug or a biosimilar?
❑ Yes ❑ No *If No, skip to #18*

16. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program? *If Yes or Unknown, skip to #18* ❑ Yes ❑ No ❑ Unknown

17. Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?
❑ Yes ❑ No

18. Has the patient ever received (including current utilizers) any of the following? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried.***
❑ A biologic (e.g., Humira, Cimzia, Enbrel) indicated for the diagnosis, *indicate biologic:* ________________
❑ Targeted synthetic disease modifying drug (e.g., Rinvoq, Xeljanz) indicated for the diagnosis
❑ Otezla
❑ No - None of the above

Complete the following section based on the patient's diagnosis, if applicable.

Section B: Crohn's Disease

19. Has the patient achieved or maintained remission? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of remission and no further questions.*** ❑ Yes ❑ No

20. *If the patient is less than 18 years old*, does the prescriber recognize that a dose above 5 mg per kg is a higher dose and the prescriber confirms that appropriate monitoring will be done? ❑ Yes ❑ No

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Remicade, Inflectra, Renflexis SGM – 10/2021.

Continuation

21. Which of the following has the patient experienced an improvement in from baseline***? ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response to therapy and no further questions.***
    - ❑ Abdominal pain or tenderness
    - ❑ Diarrhea
    - ❑ Body weight
    - ❑ Abdominal mass
    - ❑ Hematocrit
    - ❑ Endoscopic appearance of the mucosa
    - ❑ Improvement on a disease activity scoring tool (e.g., Crohn's Disease Activity Index [CDAI] score)
    - ❑ None of the above

Initiation

22. Does the patient have fistulizing disease? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation supporting diagnosis. and no further questions.*** ❑ Yes ❑ No

23. Has the patient tried and had an inadequate response to at least one conventional therapy option? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.***
    - ❑ Yes - Sulfasalazine (Azulfidine, Sulfazine)
    - ❑ Yes - Budesonide (Entocort EC)
    - ❑ Yes - Mercaptopurine (Purinethol)
    - ❑ Yes - Azathioprine (Azasan, Imuran)
    - ❑ Yes - Metronidazole (Flagyl)
    - ❑ Yes - Methotrexate IM or SC
    - ❑ Yes - Ciprofloxacin (Cipro)
    - ❑ Yes - Methylprednisolone (Solu-Medrol)
    - ❑ Yes – Prednisone
    - ❑ Yes - Rifaximin (Xifaxan)
    - ❑ Yes - Tacrolimus
    - ❑ No

24. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], budesonide [Entocort EC], ciprofloxacin [Cipro], mercaptopurine [Purinethol], methylprednisolone [Solu-Medrol], methotrexate IM or SC, metronidazole [Flagyl], prednisone, sulfasalazine [Azulfidine, Sulfazine], rifaximin [Xifaxan], tacrolimus)? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No

Section C: Ulcerative Colitis

25. What is the patient's age?
    - ❑ Less than 18 years old *Skip to #27*
    - ❑ 18 years of age or older

26. Was the patient on a dose exceeding 5 mg per kg as a pediatric patient and is continuing that dose into adulthood?
    ❑ Yes ❑ No

27. Does the prescriber recognize that a dose above 5 mg per kg is a higher dose and the prescriber confirms that appropriate monitoring will be done? ❑ Yes ❑ No

Continuation

28. Has the patient achieved or maintained remission? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of remission and no further questions.*** ❑ Yes ❑ No

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Remicade, Inflectra, Renflexis SGM – 10/2021.
Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076

Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.jhhc.com

29. Which of the following has the patient experienced an improvement in from baseline***? ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response to therapy and no further questions.***
    - ❑ Stool frequency
    - ❑ Rectal bleeding
    - ❑ Urgency of defecation
    - ❑ C-reactive protein (CRP)
    - ❑ Fecal calprotectin (FC)
    - ❑ Endoscopic appearance of the mucosa
    - ❑ Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo Score])
    - ❑ None of the above

Initiation

30. Has the patient been hospitalized for fulminant ulcerative colitis (e.g., continuous bleeding, severe toxic symptoms, including fever and anorexia)? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of hospitalization and no further questions.*** ❑ Yes ❑ No

31. Has the patient tried and had an inadequate response to at least one conventional therapy option? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.***
    - ❑ Yes - Azathioprine (Azasan, Imuran)
    - ❑ Yes - Corticosteroid (e.g., budesonide [Entocort, Uceris], hydrocortisone [Cortifoam, Colocort, Solu-Cortef, Cortef], methylprednisolone [Medrol, Solu-Medrol], prednisone)
    - ❑ Yes - Cyclosporine (Sandimmune)
    - ❑ Yes - Mesalamine (e.g., Apriso, Asacol, Lialda, Pentasa, Canasa, Rowasa), balsalazide, or olsalazine
    - ❑ Yes - Mercaptopurine (Purinethol)
    - ❑ Yes - Sulfasalazine
    - ❑ Yes - Tacrolimus (Prograf)
    - ❑ Yes - Metronidazole (Flagyl) or ciprofloxacin (Cipro) (for pouchitis only)
    - ❑ No

32. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], corticosteroid [e.g., budesonide, [Entocort, Uceris], hydrocortisone, methylprednisolone, prednisone], cyclosporine [Sandimmune], mesalamine [Asacol, Lialda, Pentasa, Canasa, Rowasa], balsalazide, olsalazine, mercaptopurine [Purinethol], sulfasalazine, tacrolimus [Prograf], metronidazole/ciprofloxacin [for pouchitis only])? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including clinical reason to avoid therapy***. ❑ Yes ❑ No

<u>Section D: Rheumatoid Arthritis and Reactive Arthritis</u>

Continuation

33. *If the diagnosis is rheumatoid arthritis,* has the patient achieved or maintained positive clinical response since starting treatment with the requested drug? ❑ Yes ❑ No

34. *If diagnosis is reactive arthritis*, has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition (e.g., tender joint count, swollen joint count, or pain)? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation supporting positive clinical response and no further questions.*** ❑ Yes ❑ No

35. What is the percent of disease activity improvement from baseline in tender joint count, swollen joint count, pain, or disability? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.*** _________%
No further questions.

Initiation – for diagnosis of Reactive Arthritis, skip to #40

36. Is the requested medication being prescribed in combination with methotrexate or leflunomide?
❑ Yes ❑ No ***If No, indicate clinical reason for not using methotrexate or leflunomide:*** ________________
____

37. Does the patient meet BOTH of the following: a) the patient was tested for the rheumatoid factor (RF) biomarker AND b) the RF biomarker test was positive? ***ACTION REQUIRED: If 'Yes', please attach laboratory results, chart notes, or medical record documentation of biomarker testing and skip to #40.*** ❑ Yes ❑ No

38. Does the patient meet BOTH of the following: a) the patient was tested for the anti-cyclic citrullinated peptide (anti-CCP) biomarker AND b) the anti-CCP biomarker test was positive? ***ACTION REQUIRED: If 'Yes', please attach laboratory results, chart notes, or medical record documentation of biomarker testing and skip to #40.***
❑ Yes ❑ No

39. Has the patient been tested for the rheumatoid factor (RF) biomarker? ***ACTION REQUIRED: If 'Yes', please attach laboratory results, chart notes, or medical record documentation of biomarker testing.*** ❑ Yes ❑ No

40. Has the patient been tested for the anti-cyclic citrullinated peptide (anti-CCP) biomarker? ***ACTION REQUIRED: If 'Yes', please attach laboratory results, chart notes, or medical record documentation of biomarker testing.***
❑ Yes ❑ No

41. Has the patient been tested for the C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) biomarker(s)? ***ACTION REQUIRED: If 'Yes', please attach laboratory results, chart notes, or medical record documentation of biomarker testing.*** ❑ Yes ❑ No

42. Please indicate if the patient tested positive or negative for the C-reactive protein (CRP) biomarker, or if the test was not completed.
❑ Positive for CRP
❑ Negative for CRP
❑ Test for CRP was not completed

43. Please indicate if the patient tested positive or negative for the erythrocyte sedimentation rate (ESR) biomarker, or if the test was not completed.
❑ Positive for ESR
❑ Negative for ESR
❑ Test for ESR was not completed

44. Has the patient experienced an inadequate response after at least 3 months of treatment with methotrexate at a dose greater than or equal to 20 mg per week? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. Indicate below and no further questions.*** ❑ Yes ❑ No

45. Has the patient experienced an intolerance to methotrexate? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. Indicate below and no further questions.*** ❑ Yes ❑ No

46. Does the patient have a contraindication to methotrexate? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including clinical reason to avoid therapy.*** ❑ Yes ❑ No
If Yes, indicate the contraindication: ____

Section E: Ankylosing Spondylitis or Active Axial Spondyloarthritis

Continuation

47. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response to therapy and no further questions.***
❑ Functional status ❑ Inflammation (e.g., morning stiffness)
❑ Total spinal pain ❑ None of the above

Initiation

48. Has the patient experienced an inadequate response with at least TWO nonsteroidal anti-inflammatory drugs (NSAIDs), or has an intolerance or contraindication to at least two NSAIDs? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No

Section F: Psoriatic Arthritis

Continuation

49. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response***.
❑ Number of swollen joints
❑ Number of tender joints
❑ Dactylitis
❑ Enthesitis
❑ Skin and/or nail involvement
❑ None of the above

Section G: Plaque Psoriasis

Continuation

50. Has the patient experienced a reduction in body surface area (BSA) affected from baseline? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of decreased body surface area affected.*** ❑ Yes ❑ No

51. Has the patient experienced an improvement in signs and symptoms of the condition from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of improvement in signs and symptoms.*** ❑ Yes ❑ No

Initiation

52. Are crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) affected? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of affected areas and body surface area affected.*** ❑ Yes ❑ No

53. What is the percentage of body surface area (BSA) affected (prior to starting the requested medication)? ***ACTION REQUIRED: Please attach chart notes or medical record documentation of affected areas and body surface area affected.*** ____________% *If greater than or equal to 10% of BSA, no further questions.*

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Remicade, Inflectra, Renflexis SGM – 10/2021.

54. Has the patient experienced an inadequate response, or has an intolerance to phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine or acitretin? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No

55. Does the patient have a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine and acitretin? ***ACTION REQUIRED: If 'Yes', please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No
    If Yes, indicate the clinical reason: ____

Section H: Juvenile Idiopathic Arthritis

Continuation

56. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.***
    ❑ Number of joints with active arthritis (e.g., swelling, pain, limitation of motion)
    ❑ Number of joints with limitation of movement
    ❑ Functional ability
    ❑ None of the above

Initiation

57. Has the patient experienced an inadequate response to ANY of the following? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy.***
    Indicate below and no further questions.
    ❑ At least 1 month trial of NSAIDs
    ❑ At least 2 weeks of treatment with corticosteroids (e.g. prednisone, methylprednisolone)
    ❑ At least 3 months of treatment with methotrexate
    ❑ At least 3 months of treatment with leflunomide
    ❑ No – No history of an inadequate response to any of the above

Section I: Behcet's Disease

58. Has the patient had an inadequate response to at least one nonbiologic medication for Behcet's disease (e.g., apremilast, colchicine, systemic glucocorticoids, azathioprine)? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy*** ❑ Yes ❑ No

Section J: Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Pyoderma Gangrenosum, Sarcoidosis. and Takayasu's Arteritis

59. Has the patient experienced ANY of the following with corticosteroids or immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil)?
    ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and documentation of clinical reason to avoid therapy. Indicate ALL that apply.
    ❑ Corticosteroids ❑ Inadequate response ❑ Intolerance ❑ Contraindication
    ❑ Immunosuppressive therapy ❑ Inadequate response ❑ Intolerance ❑ Contraindication
    If immunosuppressive therapy, specify therapy: ____
    ❑ None of the above

Section K: Hidradenitis Suppurativa

Continuation

60. Which of the following has the patient experienced since starting treatment with the requested drug? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.***
    - ❑ Reduction in abscess and inflammatory nodule count from baseline
    - ❑ Reduced formation of new sinus tracts and scarring
    - ❑ Decrease in frequency of inflammatory lesions from baseline
    - ❑ Reduction in pain from baseline
    - ❑ Reduction in suppuration from baseline
    - ❑ Improvement in frequency of relapses from baseline
    - ❑ Improvement in quality of life from baseline
    - ❑ Improvement on a disease severity assessment tool from baseline
    - ❑ None of the above

Initiation

61. Has the patient experienced an inadequate response after at least 90 days of treatment with oral antibiotics? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.***
    ❑ Yes ❑ No

62. Has the patient experienced an intolerable adverse effect to oral antibiotics? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.*** ❑ Yes ❑ No

63. Does the patient have a contraindication to oral antibiotics? ACTION REQUIRED: If 'Yes', please attach documentation of clinical reason to avoid therapy. ❑ Yes ❑ No

Section L: Uveitis

Continuation

64. Which of the following has the patient experienced since starting treatment with the requested drug? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response***.
    - ❑ Reduced frequency of recurrence compared to baseline
    - ❑ Zero anterior chamber inflammation or reduction in anterior chamber inflammation compared to baseline
    - ❑ Decreased reliance on topical corticosteroids
    - ❑ None of the above

Initiation

65. Has the patient experienced ANY of the following with corticosteroids or immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil)? ***Indicate ALL that apply. ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy, or clinical reason to avoid therapy.***
    - ❑ Corticosteroid ❑ Inadequate response ❑ Intolerance ❑ Contraindication
    - ❑ Immunosuppressive therapy ❑ Inadequate response ❑ Intolerance ❑ Contraindication

    If immunosuppressive therapy, specify therapy: ______________________________
    - ❑ None of the above

Section M: Immune Checkpoint Inhibitor Toxicity

66. Has the patient experienced an inadequate response to corticosteroids? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions***. ❑ Yes ❑ No

67. Has the patient experienced an intolerance to corticosteroids? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions***. ❑ Yes ❑ No

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Remicade, Inflectra, Renflexis SGM – 10/2021.

Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076

Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.jhhc.com

68. Does the patient have a contraindication to corticosteroids? ***ACTION REQUIRED: If 'Yes', please attach documentation of clinical reason to avoid therapy and no further questions.*** ❑ Yes ❑ No

69. Does the patient have cardiac toxicity? ❑ Yes ❑ No

Section N: Acute Graft Versus Host Disease

70. Has the patient experienced an inadequate response to systemic corticosteroids? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions***. ❑ Yes ❑ No

71. Does the patient have an intolerance or contraindication to corticosteroids? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X____

Prescriber or Authorized Signature **Date (mm/dd/yy)**